FDA EIR - Dr. Reddy's Laboratories Louisiana LLC - February 21, 2019

An FDA inspection of Dr. Reddy's Laboratories Louisiana LLC, a prescription and generic drug manufacturer in Shreveport, LA, was conducted from February 19-21, 2019. This scheduled follow-up inspection assessed the company's adherence to regulatory standards across its quality, materials, equipment, facilities, production, and packaging/labeling systems. While no formal FDA-483 observations were issued, several questionable practices were identified and discussed with management. Key issues included deficiencies in validation deviation documentation, structural defects within controlled manufacturing environments, and inadequate monitoring of critical system components and their storage integrity. The inspection also noted standard operating procedure requirements that were difficult to monitor, insufficient service contract agreements (e.g., uniform laundering), and inadequate oversight of visual inspection employees' capabilities, including unreviewed eye exam results. Inaccuracies in vendor qualifications were also highlighted. The company's management acknowledged these observations and committed to evaluating and correcting the identified deficiencies. Promised actions included retraining staff on validation documentation, addressing structural defects, implementing procedures to monitor system microbial integrity, reviewing and revising unclear SOPs, enhancing the review of employee medical evaluations for visual inspection roles, and thoroughly reviewing vendor audit schedules and agreements.